The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on December 22, 2025

Dec. 22, 2025

Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy

GlobeNewswire

Dec. 22, 2025

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

GlobeNewswire

Dec. 22, 2025

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

GlobeNewswire

Dec. 22, 2025

Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class Treatments for Chronic Kidney Disease

GlobeNewswire

Dec. 22, 2025

Nasus Pharma CEO Issues 2025 Letter to Shareholders

GlobeNewswire

Dec. 22, 2025

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

GlobeNewswire

Dec. 22, 2025

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

GlobeNewswire

Dec. 22, 2025

CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

GlobeNewswire

Dec. 22, 2025

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

GlobeNewswire

Dec. 22, 2025

ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors

GlobeNewswire

Dec. 22, 2025

XOMA Royalty Declares Quarterly Preferred Stock Dividends

GlobeNewswire

Dec. 22, 2025

Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study

GlobeNewswire

Dec. 22, 2025

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

GlobeNewswire

Dec. 22, 2025

Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

GlobeNewswire

Dec. 22, 2025

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

GlobeNewswire

Dec. 22, 2025

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

GlobeNewswire

Dec. 22, 2025

Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor

GlobeNewswire

Dec. 22, 2025

和誉医药CSF-1R抑制剂贝捷迈®获NMPA批准，填补中国腱鞘巨细胞瘤系统性治疗空白

GlobeNewswire

Dec. 22, 2025

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

GlobeNewswire

Dec. 22, 2025

Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer

GlobeNewswire